TPS107 Background: Bevacizumab with chemotherapy improves progression-free survival in patients with metastatic breast cancer (Miller K et al. N Engl J Med. 2007 Dec 27;357[26]:2666-76.) Inhibition of the VEGFR pathway appears to be an effective treatment strategy in metastatic breast cancer. Pazopanib is an oral small molecule receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDFGR-beta, and c-kit. A phase I study of pazopanib in combination with weekly paclitaxel defined the optimally tolerated regimen as 80 mg/m2 of paclitaxel and 800 mg of pazopanib. Clinical activity at these doses demonstrated a PR in 5/16 (31%) patients and stable disease > 8 weeks in 10/16 (63%) patients (Tan A JCO 26: 2008 (May 20 suppl; abstr 3552). The purpose of this trial is to determine the activity and safety profile of pazopanib with chemotherapy in women with LABC. Methods: Women with HER2-negative LABC will receive preoperative standard AC on day 1 every 21 days for four cycles. This is followed by weekly paclitaxel 80 mg/m2 IV on days 1, 8, and 15 every 28 days for four cycles given concurrently with pazopanib 800 mg po daily starting with the first paclitaxel dose. Postoperatively, pazopanib will be given 800 mg po daily for 6 months. The primary endpoint is pathologic complete response rate (pCR) in the breast and lymph nodes. One hundred patients will be enrolled in this study. As of January 2010, 10 patients have been enrolled in this trial. This clinical trial is being conducted through the support of GlaxoSmithKline. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration IDDI GlaxoSmithKline IDDI GlaxoSmithKline